Tumor-associated trypsin inhibitor (TATI) in bone diseases.

Scand J Clin Lab Invest Suppl

Department of Respiratory Physiology, Molinette Hospital, Torino, Italy.

Published: March 1992

The casual observation of high serum levels in (TATI) of tumor associated trypsin inhibitor in patients with osteosarcoma inspired us to evaluate the use of this peptide in the diagnosis of various bone diseases. We determined the serum concentrations of TATI in 35 patients with various bone diseases, i.e. degenerative diseases, bone metastasis and osteosarcomas. The cut off, determined as the 99th percentile of TATI serum levels in healthy volunteers was 32 micrograms/l. TATI has a better sensitivity in osteosarcomas (83%) than in metastatic bone diseases (33%). Its specificity in non-malignant bone diseases was not exceptional (82%). This is probably because TATI may also behave as on acute phase protein, the levels of which can rise in non-malignant diseases and also as a result of a tissue reaction in primary bone tumors.

Download full-text PDF

Source
http://dx.doi.org/10.3109/00365519109104631DOI Listing

Publication Analysis

Top Keywords

bone diseases
20
trypsin inhibitor
8
serum levels
8
bone
7
diseases
7
tati
6
tumor-associated trypsin
4
inhibitor tati
4
tati bone
4
diseases casual
4

Similar Publications

Effects of denosumab and zoledronic acid on postmenopausal osteoporosis, bone density, and fat-free mass.

Arch Osteoporos

January 2025

Division of Endocrinology & Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Unlabelled: This study compared denosumab and zoledronic acid for treating osteoporosis in drug-naïve postmenopausal Korean women. Over 3 years, both drugs significantly increased bone mineral density. However, denosumab also improved fat-free mass, suggesting it may be a better initial treatment for osteoporosis with low muscle mass, assuming all other conditions remain constant.

View Article and Find Full Text PDF

Tumor-induced osteomalacia (TIO) is a rare acquired paraneoplastic syndrome caused by a mesenchymal tumor secreting a phosphaturic hormone called FGF23. Patients present with bone pain, fragility fractures and muscle weakness. Biochemical results show hypophosphatemia, raised serum alkaline phosphatase and reduced calcitriol.

View Article and Find Full Text PDF

This study aimed to explore the perceptions of patients and rheumatologists about a treat-to-target (T2T) strategy in axial spondyloarthritis (axSpA) and identify the barriers and facilitators to its implementation in clinical practice. A mixed methods design was applied. Patients with axSpA who visited the outpatient clinic with active disease (AxSpA Disease Activity Score [ASDAS] ≥ 2.

View Article and Find Full Text PDF

Study Design: Retrospective cohort study.

Background: Sciatic scoliosis is attributed to non-structural scoliosis resulting from the irritation of spinal nerve roots. Although limited research has addressed the specific characteristics of sciatic scoliotic curve patterns, there is a lack of reported data on the pre- and post-radiographic outcomes of patients with sciatic scoliosis caused by lumbar disc herniation who have undergone full-endoscopic interlaminar discectomy (FEID).

View Article and Find Full Text PDF

Objective: Pedicle screw loosening is one of the common complications in elderly patients undergoing transforaminal lumbar interbody fusion (TLIF) for lumbar spine disease. Malnutrition, prevalent among elderly patients, has been shown to be associated with increased complications. The Geriatric Nutritional Risk Index (GNRI) serves as a simple indicator of nutritional status.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!